Pharmaceutical

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.

Oct 3, 2023 - 20:00
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.
Read the original article

Tags:

Previous Article

Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of A...

Next Article

CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lym...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ikena further sheds staff and pipeline in bid to maximise value

Ikena further sheds staff and pipeline in bid to maximi...

May 31, 2024

Merck reports drop in net income for fiscal 2023

Merck reports drop in net income for fiscal 2023

Mar 7, 2024

STAT+: Ohio attorney general accuses pharmacy benefit managers of drug price fixing

STAT+: Ohio attorney general accuses pharmacy benefit m...

Mar 28, 2023